

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

VOLUNTARY ANNOUNCEMENT

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**” or “**WuXi AppTec**”) on a voluntary basis.

Reference is made to the announcements of the Company dated January 26, 2024, January 29, 2024, February 4, 2024, February 13 and March 7, 2024, in relation to, among other things, WuXi AppTec being named in certain proposed legislation that was introduced in the U.S. House of Representatives (the “**House**”) and the U.S. Senate.

The Company has learned that on May 15, 2024 the U.S. House Committee on Oversight and Accountability (the “**House Committee**”) voted to report to the House a draft bill H.R.8333 (“**Bill H.R.8333**”), which is an amended version of the predecessor bill H.R.7085 for the proposed Biosecure Act. Bill H.R.8333 incorporates certain amendments including, among others, the removal of certain alleged findings against WuXi AppTec and the addition of a “grandfather” clause that exempts existing contracts entered into before the effectiveness of the proposed restrictions. However, despite existing processes at U.S. government agencies for evaluating national security concerns, Bill H.R.8333 still includes WuXi AppTec’s name within the definition of a “biotechnology company of concern”, which is a preemptive and unjustified designation without due process that the Company strongly object to. We firmly believe that WuXi AppTec has not posed, does not pose, and will not pose a security risk to the United States or any other country and it has not been subject to any sanction by the U.S. government agencies. We also reiterate that WuXi AppTec does not have a human genomics business or collect human genomic data in the U.S., China or elsewhere.

Bill H.R.8333 will continue to go through the legislative process in the House in the coming months. The Company will work closely with its advisors to continue our engagement and dialogue with the relevant stakeholders involved in the ongoing legislative process for Bill H.R.8333 and the corresponding bill S.3558 that was voted by the Senate Committee on Homeland Security and Government Affairs on March 6, 2024, the contents of which need to be reconciled and remain subject to further review and changes.

Founded with the purposes of serving our customers' needs and helping patients, WuXi AppTec has become a trusted and longstanding partner in the global healthcare community, where for more than twenty years the Company has helped thousands of global customers with discovery, development, and manufacturing efforts to deliver innovative and life-saving medicines that meet the highest regulatory and quality standards in the pharmaceutical and life science industry. We look forward to continuing our mission to serve customers and help patients around the world.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, May 16, 2024

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.

* *For identification purposes only*